| Identifiers | |
|---|---|
|
|
| Synonyms | N,N-Didesmethyl-4,4'-dihydroxytamoxifen |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C24H25NO3 |
| Molar mass | 375.47 g·mol−1 |
| 3D model (Jmol) | |
|
|
|
|
4'-Hydroxynorendoxifen is a synthetic, non-steroidal antiestrogen of the triphenylethylene group. It is a dual selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), and was derived from tamoxifen, a SERM, and norendoxifen, a metabolite of tamoxifen that has been found to act as an AI. The drug has been suggested for potential development as a treatment for estrogen receptor (ER)-positive breast cancer. It was synthesized in 2015.